# Prologis, Inc.: financial statements, quarterly

PLD · NYSE · CIK 1045609 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pld.md) · [Financials](/companies/pld/financials.md) · [Filings](/companies/pld/filings.md) · [Insiders](/companies/pld/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pld/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,451](/filings/0000950170-25-021272.md) | [1,915](/filings/0000950170-25-021272.md) | [1,889](/filings/0000950170-25-021272.md) | [1,957](/filings/0001193125-26-051453.md) | [2,008](/filings/0001193125-26-051453.md) | [2,036](/filings/0001193125-26-051453.md) | [2,201](/filings/0001193125-26-051453.md) | [2,140](/filings/0001193125-26-197850.md) | [2,184](/filings/0001193125-26-051453.md) | [2,214](/filings/0001193125-26-051453.md) | [2,253](/filings/0001193125-26-051453.md) | [2,298](/filings/0001193125-26-197850.md) |
| Operating income | $m | [1,412](/filings/0000950170-25-021272.md) | [882](/filings/0000950170-25-021272.md) | [835](/filings/0000950170-25-021272.md) | [720](/filings/0001193125-26-051453.md) | [1,023](/filings/0001193125-26-051453.md) | [1,251](/filings/0001193125-26-051453.md) | [1,421](/filings/0001193125-26-051453.md) | [878](/filings/0001193125-26-197850.md) | [913](/filings/0001193125-26-051453.md) | [940](/filings/0001193125-26-051453.md) | [1,626](/filings/0001193125-26-051453.md) | [1,211](/filings/0001193125-26-197850.md) |
| Interest expense | $m | [150](/filings/0000950170-24-086882.md) | [181](/filings/0000950170-23-055980.md) | [174 d](/filings/0001193125-26-051453.md) | [193](/filings/0000950170-24-048421.md) | [208](/filings/0000950170-24-086882.md) | [230](/filings/0001193125-25-253512.md) | [232 d](/filings/0001193125-26-051453.md) | [232](/filings/0001193125-26-197850.md) | [252](/filings/0000950170-25-099770.md) | [258](/filings/0001193125-25-253512.md) | [260 d](/filings/0001193125-26-051453.md) | [254](/filings/0001193125-26-197850.md) |
| Income tax | $m | [79.2](/filings/0000950170-24-086882.md) | [41.2](/filings/0000950170-24-117407.md) | [58.5 d](/filings/0001193125-26-051453.md) | [32.8](/filings/0000950170-25-060107.md) | [43.1](/filings/0000950170-25-099770.md) | [4.2](/filings/0001193125-25-253512.md) | [86.9 d](/filings/0001193125-26-051453.md) | [43.4](/filings/0001193125-26-197850.md) | [23.4](/filings/0000950170-25-099770.md) | [54.5](/filings/0001193125-25-253512.md) | [82.7 d](/filings/0001193125-26-051453.md) | [48.0](/filings/0001193125-26-197850.md) |
| Net income | $m | [1,216](/filings/0000950170-24-086882.md) | [748](/filings/0000950170-24-117407.md) | [676](/filings/0000950170-25-021272.md) | [586](/filings/0000950170-25-060107.md) | [861](/filings/0000950170-25-099770.md) | [1,006](/filings/0001193125-25-253512.md) | [1,342](/filings/0001193125-26-051453.md) | [593](/filings/0001193125-26-197850.md) | [571](/filings/0000950170-25-099770.md) | [764](/filings/0001193125-25-253512.md) | [1,482](/filings/0001193125-26-051453.md) | [982](/filings/0001193125-26-197850.md) |
| Diluted EPS | $ per share | [1.31](/filings/0000950170-25-021272.md) | [0.80](/filings/0000950170-25-021272.md) | [0.68](/filings/0000950170-25-021272.md) | [0.63](/filings/0001193125-26-051453.md) | [0.92](/filings/0001193125-26-051453.md) | [1.08](/filings/0001193125-26-051453.md) | [1.37](/filings/0001193125-26-051453.md) | [0.63](/filings/0001193125-26-197850.md) | [0.61](/filings/0001193125-26-051453.md) | [0.82](/filings/0001193125-26-051453.md) | [1.49](/filings/0001193125-26-051453.md) | [1.05](/filings/0001193125-26-197850.md) |
| Basic EPS | $ per share | [1.31](/filings/0000950170-25-021272.md) | [0.81](/filings/0000950170-25-021272.md) | [0.68](/filings/0000950170-25-021272.md) | [0.63](/filings/0001193125-26-051453.md) | [0.93](/filings/0001193125-26-051453.md) | [1.08](/filings/0001193125-26-051453.md) | [1.38](/filings/0001193125-26-051453.md) | [0.64](/filings/0001193125-26-197850.md) | [0.61](/filings/0001193125-26-051453.md) | [0.82](/filings/0001193125-26-051453.md) | [1.50](/filings/0001193125-26-051453.md) | [1.05](/filings/0001193125-26-197850.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.5](/filings/0000950170-23-034768.md) | [0.7](/filings/0000950170-23-055980.md) | [0.5](/filings/0001193125-26-051453.md) | [0.5](/filings/0000950170-24-048421.md) | [0.6](/filings/0000950170-24-086882.md) | [0.8](/filings/0000950170-24-117407.md) | [1.3](/filings/0001193125-26-051453.md) | [0.7](/filings/0000950170-25-060107.md) | [1.1](/filings/0000950170-25-099770.md) | [1.2](/filings/0001193125-25-253512.md) | [1.1](/filings/0001193125-26-197850.md) | [0.9](/filings/0001193125-26-197850.md) |
| Total assets | $bn | [92.4](/filings/0000950170-23-034768.md) | [91.9](/filings/0000950170-23-055980.md) | [93.0](/filings/0000950170-25-021272.md) | [93.3](/filings/0000950170-24-048421.md) | [93.5](/filings/0000950170-24-086882.md) | [95.9](/filings/0000950170-24-117407.md) | [95.3](/filings/0001193125-26-051453.md) | [96.0](/filings/0000950170-25-060107.md) | [97.7](/filings/0000950170-25-099770.md) | [98.3](/filings/0001193125-25-253512.md) | [98.7](/filings/0001193125-26-197850.md) | [98.1](/filings/0001193125-26-197850.md) |
| Total liabilities | $bn | [34.3](/filings/0000950170-23-034768.md) | [33.7](/filings/0000950170-23-055980.md) | [35.2](/filings/0000950170-25-021272.md) | [35.5](/filings/0000950170-24-048421.md) | [35.6](/filings/0000950170-24-086882.md) | [38.2](/filings/0000950170-24-117407.md) | [36.7](/filings/0001193125-26-051453.md) | [37.9](/filings/0000950170-25-060107.md) | [40.4](/filings/0000950170-25-099770.md) | [41.1](/filings/0001193125-25-253512.md) | [41.0](/filings/0001193125-26-197850.md) | [40.2](/filings/0001193125-26-197850.md) |
| Long-term debt | $bn | [28.1](/filings/0000950170-23-034768.md) | [27.6](/filings/0000950170-23-055980.md) | [29.0](/filings/0000950170-25-021272.md) | [29.6](/filings/0000950170-24-048421.md) | [29.9](/filings/0000950170-24-086882.md) | [32.3](/filings/0000950170-24-117407.md) | [30.9](/filings/0001193125-26-051453.md) | [32.3](/filings/0000950170-25-060107.md) | [34.7](/filings/0000950170-25-099770.md) | [35.3](/filings/0001193125-25-253512.md) | [35.0](/filings/0001193125-26-197850.md) | [34.7](/filings/0001193125-26-197850.md) |
| Shareholders' equity | $bn | [53.5](/filings/0000950170-23-034768.md) | [53.6](/filings/0000950170-23-055980.md) | [53.2](/filings/0000950170-25-021272.md) | [53.2](/filings/0000950170-24-048421.md) | [53.3](/filings/0000950170-24-086882.md) | [53.1](/filings/0000950170-24-117407.md) | [54.0](/filings/0001193125-26-051453.md) | [53.5](/filings/0000950170-25-060107.md) | [52.7](/filings/0000950170-25-099770.md) | [52.6](/filings/0001193125-25-253512.md) | [53.2](/filings/0001193125-26-197850.md) | [53.5](/filings/0001193125-26-197850.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,215 d](/filings/0000950170-24-086882.md) | [1,969 d](/filings/0000950170-24-117407.md) | [1,074 d](/filings/0001193125-26-051453.md) | [1,055](/filings/0000950170-25-060107.md) | [1,086 d](/filings/0000950170-25-099770.md) | [1,435 d](/filings/0001193125-25-253512.md) | [1,335 d](/filings/0001193125-26-051453.md) | [1,161](/filings/0001193125-26-197850.md) | [1,242 d](/filings/0000950170-25-099770.md) | [1,448 d](/filings/0001193125-25-253512.md) | [1,158 d](/filings/0001193125-26-051453.md) | [1,288](/filings/0001193125-26-197850.md) |
| Dividends paid | $m | [807 d](/filings/0000950170-24-086882.md) | [806 d](/filings/0000950170-24-117407.md) | [809 d](/filings/0001193125-26-051453.md) | [892](/filings/0000950170-25-060107.md) | [893 d](/filings/0000950170-25-099770.md) | [893 d](/filings/0001193125-25-253512.md) | [893 d](/filings/0001193125-26-051453.md) | [940](/filings/0001193125-26-197850.md) | [942 d](/filings/0000950170-25-099770.md) | [941 d](/filings/0001193125-25-253512.md) | [942 d](/filings/0001193125-26-051453.md) | [1,001](/filings/0001193125-26-197850.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [766](/filings/0000950170-23-034768.md) | [766](/filings/0000950170-23-055980.md) | [952](/filings/0000950170-24-048421.md) | [952](/filings/0000950170-24-086882.md) | [952](/filings/0000950170-24-117407.md) | [954](/filings/0000950170-25-060107.md) | [953](/filings/0000950170-25-099770.md) | [954](/filings/0001193125-25-253512.md) | [956](/filings/0001193125-26-197850.md) | [956](/filings/0000950170-25-099770.md) | [957](/filings/0001193125-25-253512.md) | [958](/filings/0001193125-26-197850.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 932,338,000 at 2026-04-28, from the cover of the [10-Q filed 2026-04-30](/filings/0001193125-26-197850.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.